Klick, a leading commercialization partner for life sciences companies, has acquired Oxford PharmaGenesis, a prominent HealthScience communications consultancy, for an undisclosed amount. This strategic move sees Oxford PharmaGenesis, known for its deep scientific expertise and global reach, joining Klick's expanding portfolio.
Founded in 1998, Oxford PharmaGenesis has grown to become the largest independently owned and financed company in the medical communications sector, employing over 500 talented individuals across various global locations. Its core mission is to accelerate the adoption of evidence-based innovations for patients in areas of unmet medical need, applying powerful thinking to support client success in the pharmaceutical and healthcare industries.
The acquisition is set to enhance Klick's capabilities by integrating Oxford PharmaGenesis's specialized medical communications and scientific expertise. For Klick, this represents a significant expansion of its global footprint and a deepening of its scientific and clinical communication offerings, allowing it to provide more comprehensive, integrated solutions to its life sciences clients. The strategic rationale centers on creating a more robust, full-service partner capable of guiding health innovations from scientific discovery through to commercialization and patient adoption.
For Oxford PharmaGenesis, joining Klick provides access to broader resources and a larger platform to further its mission. The integration is expected to create synergies that will benefit clients through enhanced service offerings, combining Klick's commercialization prowess with Oxford PharmaGenesis's scientific communication excellence. This union aims to deliver unparalleled value in accelerating the impact of new treatments and technologies.
The combined entity is poised to become a formidable force in the health commercialization and medical communications landscape, offering an expanded suite of services designed to navigate the complexities of bringing health innovations to patients worldwide. This acquisition underscores a commitment to driving progress in healthcare by fostering greater collaboration between scientific communication and commercial strategy.